Anti-Neutrophil Cytoplasmic Antibodies in Patients with Systemic Lupus Erythematosus

Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: An early marker of progressive erosive disease

“…Distributions of Larsen scores in rheumatoid arthritis patients who were negative for antineutrophil cytoplasmic antibodies (ANCA) and those who were positive for perinuclear ANCA (P-ANCA) during the 7-year followup. Also, the predominance of the perinuclear staining pattern in ANCA-positive RA patients is concordant with findings of previous studies (17,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). with early RA (i.e., with symptoms for Յ12 months at entry).…”

“…P ϭ 0.0015 for the difference in the rate of radiographic progression between these groups. Thus, our current findings on ANCA prevalence in RA patients are consistent with findings of earlier studies (17,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). The prognostic role of ANCA with regard to the progression of joint damage was assessed in a followup of 7 years.…”

“…Among patients with rheumatoid arthritis (RA), ANCA (pANCA, granulocyte-specific antinuclear antibodies [GS-ANA], and diffuse nongranular cANCA) have been detected in the sera of 0-70% of patients (17,(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). ANCA have also been detected in synovial fluid of patients with RA (16,27).…”

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

“…ANCA are not 100% specific for vasculitis; they are found in other autoimmune diseases and vasculitis mimics such as SLE,58 RA,59 HIV,60 tuberculosis,61 62 inflammatory bowel disease,63 primary sclerosing cholangitis,64 drug reactions (eg, cocaine65 and propylthyourracil66), infective endocarditis and septic shock 67…”

Perinuclear antineutrophil cytoplasmic antibody in rheumatoid arthritis. A marker of severe disease with associated nephropathy

“…The perinuclear ANCA (pANCA) staining pattern has been documented to occur in patients with NCGN, microscopic polyangiitis, and Churg-Strauss syndrome, the specific ANCA antigen most frequently being myeloperoxidase (MPO) (3,5-7,13). However, pANCA are far from specific for any strictly defined clinical disorder, since they have been reported to occur in many inflammatory disorders, e.g., inflammatory bowel disease and primary sclerosing cholangitis (14,15), and rheumatic diseases (16)(17)(18)(19). The target antigens for pANCA in these disorders are usually unclear, although several, such as lactoferrin, cathepsin G, human leukocyte elastase (HLE), and lysozyme, have been proposed (20).…”